Literature DB >> 9090376

Frataxin fracas.

M Cossée, V Campuzano, H Koutnikova, K Fischbeck, J L Mandel, M Koenig, S I Bidichandani, P I Patel, M D Moltè, J Cañizares, R De Frutos, L Pianese, F Cavalcanti, A Monticelli, S Cocozza, L Montermini, M Pandolfo.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9090376     DOI: 10.1038/ng0497-337

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


× No keyword cloud information.
  15 in total

1.  Atypical Friedreich ataxia caused by compound heterozygosity for a novel missense mutation and the GAA triplet-repeat expansion.

Authors:  S I Bidichandani; T Ashizawa; P I Patel
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

2.  Phosphodiesterase Inhibitors Revert Axonal Dystrophy in Friedreich's Ataxia Mouse Model.

Authors:  Belén Mollá; Diana C Muñoz-Lasso; Pablo Calap; Angel Fernandez-Vilata; María de la Iglesia-Vaya; Federico V Pallardó; Maria Dolores Moltó; Francesc Palau; Pilar Gonzalez-Cabo
Journal:  Neurotherapeutics       Date:  2019-04       Impact factor: 7.620

3.  Triple therapy with darbepoetin alfa, idebenone, and riboflavin in Friedreich's ataxia: an open-label trial.

Authors:  Javier Arpa; Irene Sanz-Gallego; Francisco J Rodríguez-de-Rivera; Francisco J Domínguez-Melcón; Daniel Prefasi; Javier Oliva-Navarro; Mar Moreno-Yangüela; Samuel I Pascual-Pascual
Journal:  Cerebellum       Date:  2013-10       Impact factor: 3.847

4.  The GAA*TTC triplet repeat expanded in Friedreich's ataxia impedes transcription elongation by T7 RNA polymerase in a length and supercoil dependent manner.

Authors:  E Grabczyk; K Usdin
Journal:  Nucleic Acids Res       Date:  2000-07-15       Impact factor: 16.971

5.  Iron in neurodegenerative disorders.

Authors:  D. Berg; G. Becker; P. Riederer; O. Riess
Journal:  Neurotox Res       Date:  2002 Nov-Dec       Impact factor: 3.911

6.  The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure.

Authors:  S I Bidichandani; T Ashizawa; P I Patel
Journal:  Am J Hum Genet       Date:  1998-01       Impact factor: 11.025

Review 7.  Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities.

Authors:  Renata Santos; Sophie Lefevre; Dominika Sliwa; Alexandra Seguin; Jean-Michel Camadro; Emmanuel Lesuisse
Journal:  Antioxid Redox Signal       Date:  2010-09-01       Impact factor: 8.401

8.  Alleviating transcript insufficiency caused by Friedreich's ataxia triplet repeats.

Authors:  E Grabczyk; K Usdin
Journal:  Nucleic Acids Res       Date:  2000-12-15       Impact factor: 16.971

Review 9.  Potential therapeutic benefits of strategies directed to mitochondria.

Authors:  Amadou K S Camara; Edward J Lesnefsky; David F Stowe
Journal:  Antioxid Redox Signal       Date:  2010-08-01       Impact factor: 8.401

10.  Limitations in a frataxin knockdown cell model for Friedreich ataxia in a high-throughput drug screen.

Authors:  Nadège Calmels; Hervé Seznec; Pascal Villa; Laurence Reutenauer; Marcel Hibert; Jacques Haiech; Pierre Rustin; Michel Koenig; Hélène Puccio
Journal:  BMC Neurol       Date:  2009-08-24       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.